Patents by Inventor Michael Martin Ollmann

Michael Martin Ollmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CDK9 as modifier of the IGF pathway and methods of use
    Patent number: 8758994
    Abstract: Human CDK9 genes are identified as modulators of the IGF pathway, and thus are therapeutic targets for disorders associated with defective IGF function. Methods for identifying modulators of IGF, comprising screening for agents that modulate the activity of CDK9 are provided.
    Type: Grant
    Filed: June 20, 2005
    Date of Patent: June 24, 2014
    Assignee: Exelixis, Inc.
    Inventors: Mark E. Maxwell, Michael Martin Ollmann, Timothy S. Heuer, Lynn Margaret Bjerke
  • PGDS as modifiers of the PTEN pathway and methods of use
    Patent number: 8288119
    Abstract: Human PGD genes are identified as modulators of the PTEN pathway, and thus are therapeutic targets for disorders associated with defective PTEN function. Methods for identifying modulators of PTEN, comprising screening for agents that modulate the activity of PGD are provided.
    Type: Grant
    Filed: June 20, 2005
    Date of Patent: October 16, 2012
    Assignee: Exelixis, Inc.
    Inventors: Chunyan Song, Michael Martin Ollmann, Lynn Margaret Bjerke
  • PSMCs As Modifiers of the RB Pathway and Methods of Use
    Publication number: 20120107827
    Abstract: Human PSMC genes are identified as modulators of the RB pathway, and thus are therapeutic targets for disorders associated with defective RB function. Methods for identifying modulators of RB, comprising screening for agents that modulate the activity of PSMC are provided.
    Type: Application
    Filed: October 12, 2011
    Publication date: May 3, 2012
    Applicant: EXELIXIS, INC.
    Inventors: ALBERT K. TAI, CHUNYAN SONG, MICHAEL MARTIN OLLMANN, LUCILE A. GILLETT, JOANNE I. ADAMKEWICZ, KIM LICKTEIG
  • ALDOs as modifiers of the IGF pathway and methods of use
    Patent number: 7927872
    Abstract: Human ALDO genes are identified as modulators of the IGF pathway, and thus are therapeutic targets for disorders associated with defective IGF function. Methods for identifying modulators of IGF, comprising screening for agents that modulate the activity of ALDO are provided.
    Type: Grant
    Filed: June 20, 2005
    Date of Patent: April 19, 2011
    Assignee: Exelixis, Inc.
    Inventors: Mark E. Maxwell, Michael Martin Ollmann, Timothy S. Heuer, Benjamin C. Hitz
  • ACACS As Modifiers of the IGF Pathway and Methods of Use
    Publication number: 20090053239
    Abstract: Human MPTEN genes are identified as modulators of the PTEN pathway, and thus are therapeutic targets for disorders associated with defective PTEN function. Methods for identifying modulators of PTEN, comprising screening for agents that modulate the activity of MPTEN are provided.
    Type: Application
    Filed: June 20, 2005
    Publication date: February 26, 2009
    Applicant: EXELIXIS, INC.
    Inventors: Mark E. Maxwell, Michael Martin Ollmann, Timothy S. Heuer, Lynn Margaret Bjerke
  • ALDOS AS MODIFIERS OF THE IGF PATHWAY AND METHODS OF USE
    Publication number: 20090022737
    Abstract: Human ALDO genes are identified as modulators of the IGF pathway, and thus are therapeutic targets for disorders associated with defective IGF function. Methods for identifying modulators of IGF, comprising screening for agents that modulate the activity of ALDO are provided.
    Type: Application
    Filed: June 20, 2005
    Publication date: January 22, 2009
    Applicant: EXELIXIS, INC.
    Inventors: Mark E. Maxwell, Michael Martin Ollmann, Timothy S. Heuer, Benjamin C. Hitz
  • PGDS AS MODIFIERS OF THE PTEN PATHWAY AND METHODS OF USE
    Publication number: 20090019558
    Abstract: Human PGD genes are identified as modulators of the PTEN pathway, and thus are therapeutic targets for disorders associated with defective PTEN function. Methods for identifying modulators of PTEN, comprising screening for agents that modulate the activity of PGD are provided.
    Type: Application
    Filed: June 20, 2005
    Publication date: January 15, 2009
    Applicant: EXELIXIS, INC.
    Inventors: Chunyan Song, Michael Martin Ollmann, Lynn Margaret Bjerke
  • Psmcs as Modifiers of the Rb Pathway and Methods of Use
    Publication number: 20090013420
    Abstract: Human PSMC genes are identified as modulators of the RB pathway, and thus are therapeutic targets for disorders associated with defective RB function. Methods for identifying modulators of RB, comprising screening for agents that modulate the activity of PSMC are provided.
    Type: Application
    Filed: August 6, 2003
    Publication date: January 8, 2009
    Inventors: Albert K. Tai, Chunyan Song, Michael Martin Ollmann, Lucile A. Gillett, Joanne I. Adamkewicz, Kim Lickteig
  • CRBs as Modifiers of Branching Morphogenesis and Methods of Use
    Publication number: 20080163386
    Abstract: Human CRB genes are identified as modulators of branching morphogenesis, and thus are therapeutic targets for disorders associated with defective branching morphogenesis function. Methods for identifying modulators of branching morphogenesis, comprising screening for agents that modulate the activity of CRB are provided.
    Type: Application
    Filed: January 28, 2007
    Publication date: July 3, 2008
    Applicant: EXELIXIS, INC.
    Inventors: Felix D. Karim, Linda Nolan Keyes, Gregory D. Plowman, Michael Martin Ollmann, Mark E. Maxwell, Thierry Tidiane Diagana
  • Insect p53 tumor suppressor genes and proteins
    Publication number: 20040161827
    Abstract: A family of p53 tumor suppressor nucleic acid and protein isolated from several insect species is described. The p53 nucleic acid and protein can be used to genetically modify metazoan invertebrate organisms, such as insects and worms, or cultured cells, resulting in p53 expression or mis-expression. The genetically modified organisms or cells can be used in screening assays to identify candidate compounds that are potential pesticidal agents or therapeutics that interact with p53 protein. They can also be used in methods for studying p53 activity and identifying other genes that modulate the function of, or interact with, the p53 gene. Nucleic acid and protein sequences for Drosophila p33 and Rb tumor suppressors are also described.
    Type: Application
    Filed: February 5, 2004
    Publication date: August 19, 2004
    Inventors: Andrew Roy Buchman, Darren Mark Platt, Michael Martin Ollmann, Lynn Marie Young, Madelyn Robin Demsky, Kevin Patrick Keegan, Lori Friedman, Casey Kopczynski, Jeffrey S. Larson, Stephanie A. Robertson
  • Methods of screening for agents that modulate the interaction of human ECT2 polypeptide with an ECT2 binding target
    Patent number: 6630297
    Abstract: Human Ect2 polypeptide, fragments and derivatives, along with vectors and host cells for expression and production of Ect2 polypeptide are provided. Various methods of screening for agents that modulate interaction of Ect2 with an Ect2 binding agent, including high throughput methods, are also provided.
    Type: Grant
    Filed: November 7, 2002
    Date of Patent: October 7, 2003
    Assignee: Exelixis, Inc.
    Inventors: Michael Martin Ollmann, Kevin Patrick Keegan, Thomas J. Stout, David Matthews, Alison Joly
  • CRBs as modifiers of branching morphogenesis and methods of use
    Publication number: 20030100005
    Abstract: Human CRB genes are identified as modulators of branching morphogenesis, and thus are therapeutic targets for disorders associated with defective branching morphogenesis function. Methods for identifying modulators of branching morphogenesis, comprising screening for agents that modulate the activity of CRB are provided.
    Type: Application
    Filed: November 25, 2002
    Publication date: May 29, 2003
    Inventors: Felix D. Karim, Linda Nolan Keyes, Gregory D. Plowman, Michael Martin Ollmann, Mark E. Maxwell, Thierry Tidiane Diagana
  • Human Ect2 and methods of use
    Publication number: 20030078382
    Abstract: Human Ect2 polypeptide, fragments and derivatives, along with vectors and host cells for expression and production of Ect2 polypeptide are provided. Various methods of screening for agents that modulate interaction of Ect2 with an Ect2 binding agent, including high throughput methods, are also provided.
    Type: Application
    Filed: November 7, 2002
    Publication date: April 24, 2003
    Inventors: Michael Martin Ollmann, Kevin Patrick Keegan, Thomas J. Stout, David Matthews, Alison Joly
  • Human ECT2 polypeptide
    Patent number: 6515109
    Abstract: Human Ect2 polypeptide, fragments and derivatives, along with vectors and host cells for expression and production of Ect2 polypeptide are provided. Various methods of screening for agents that modulate interaction of Ect2 with an Ect2 binding agent, including high throughput methods, are also provided.
    Type: Grant
    Filed: October 12, 2001
    Date of Patent: February 4, 2003
    Assignee: Exelixis, Inc.
    Inventors: Michael Martin Ollmann, Kevin Patrick Keegan, Thomas J. Stout, David Matthews, Alison Joly